重组人白细胞介素-11与海曲泊帕乙醇胺片对乳腺癌化疗所致血小板减少症的疗效对比  

Comparison of efficacy of recombinant human interleukin-11 and herombopag olamine tablets on chemotherapy-induced thrombocytopenia in breast cancer

作　　者：王超[1] 张俊梅 张鹏[1] 刘力 王晓春[1] WANG Chao;ZHANG Junmei;ZHANG Peng;LIU Li;WANG Xiaochun(Department of Breast Surgery,Hebei University Affiliated Hospital,Baoding 071000,China;Department of Pathology,Luannan County Hospital)

机构地区：[1]河北大学附属医院乳腺外科,071000 [2]滦南县医院病理科

出　　处：《天津医药》2025年第4期365-369,共5页Tianjin Medical Journal

基　　金：河北省医学科学研究课题计划项目(20231500)。

摘　　要：目的对比重组人白细胞介素-11(rhIL-11)与海曲泊帕乙醇胺片治疗乳腺癌化疗所致血小板减少症(CIT)的疗效。方法前瞻性选择乳腺癌CIT患者86例,随机分为对照组(给予rhIL-11)和研究组(给予海曲泊帕乙醇胺片),2组各43例。治疗前和治疗14 d后,采用全自动血液分析仪检测血小板参数[血小板计数(PLT)、血小板压积(PCT)、血小板分布宽度(PDW)、平均血小板体积(MPV)],流式细胞仪检测细胞免疫指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)),酶联免疫吸附试验检测血小板生成素(TPO)、白细胞介素-11(IL-11),比较2组间和每组治疗前后上述指标水平,并记录2组不良反应发生情况。结果治疗后,2组患者PLT、PCT、CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)、TPO、IL-11均高于治疗前,且研究组高于对照组(P<0.05);2组治疗后的PDW、MPV、CD8^(+)均低于治疗前,且研究组低于对照组(P<0.05)。2组不良反应总发生率差异无统计学意义(P>0.05)。结论rhIL-11、海曲泊帕乙醇胺片治疗乳腺癌CIT均有效,海曲泊帕乙醇胺片在改善血小板参数、细胞免疫指标、TPO、IL-11方面较rhIL-11更具优势,且未增加不良反应的发生。Objective To compare the efficacy of recombinant human interleukin-11(rhIL-11)and herombopag olamine tablets on chemotherapy-induced thrombocytopenia(CIT)in breast cancer.Methods Eighty-six prospectively selected breast cancer patients with CIT were randomly divided into the control group(administered rhIL-11)and the study group(administered herombopag olamine tablets),with 43 cases in each group.Before treatment and 14 days after treatment,platelet parameters[platelet count(PLT),plateletcrit(PCT),platelet distribution width(PDW)and mean platelet volume(MPV)]and flow cytometry were measured by automated hematology analyzer.Cellular immune indicators(CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+))were detected by flow cytometer.Enzyme-linked immunosorbent assay was used to determine the levels of thrombopoietin(TPO)and interleukin-11(IL-11).The above parameters were compared between the two groups,and the incidence of adverse reactions in the two groups was recorded.Results After treatment,PLT,PCT,CD3^(+),CD4^(+),CD4^(+)/CD8^(+),TPO and IL-11 in both groups were higher than before treatment,and which was higher in the study group than the control group(P<0.05).After treatment,PDW,MPV and CD8^(+)of both groups were lower than before treatment,and the study group was lower than the control group(P<0.05).There was no significant difference in the overall incidence of adverse reactions between the two groups(P>0.05).Conclusion Both rhIL-11 and herombopag olamine tablets are effective in treating breast cancer with CIT.Compared with rhIL-11,herombopag olamine tablets have more advantages in improving platelet parameters,cellular immune indicators,TPO and IL-11,and do not increase the adverse reactions.

关 键 词：白细胞介素11 乙醇胺 血小板减少 乳腺肿瘤 海曲泊帕乙醇胺片 

分 类 号：R969.4[医药卫生—药理学]